Thu, Sep 18, 2014, 2:43 PM EDT - U.S. Markets close in 1 hr 17 mins

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • geterginto geterginto Apr 17, 2013 9:09 PM Flag

    questions

    is there any worry that eteplirsen wouldn't receive accelerated approval allowing GlaxoSmithKline to reach the U.S. market first with its competing Duchenne muscular dystrophy (DMD) drug drisapersen

    also what is the potential market cap if they do get approval would it go as high triple giving a 3.5 billion market cap...or is it that too optimistic

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • sdijc@earthlink.net sdijc Apr 17, 2013 10:46 PM Flag

      You butcher the English language. Have you ever heard of punctuation? You're lucky. You probably went to public school. The nuns would have kicked your butt.

      Sentiment: Strong Buy

    • It is questionable whether Drisapirsen gets approved based on their lack of quality data. If eterplirsen was not out there it is possible that Drisa would be approved because there is no known therapeutic that ameliorates the cytopathology of Duchennes. Glaxo has a future datapoint that is critical to the development of that therapeutic [use that term loosely]. If their total dystrophin #'s are low compared to baseline, that program is dead. Glaxo will pull the plug. remember that the magic number for total dystrophin to have an positive clinical effect is somewhere between 15 and 20%. Disregard positive fibers We must see total dystrophin from Glaxo..

      Sentiment: Strong Buy

 
SRPT
22.40-0.54(-2.35%)2:43 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.